Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other financing activities (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Other financing activities for 4 consecutive years, with $344000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Other financing activities changed N/A year-over-year to $344000.0, compared with a TTM value of $344000.0 through Dec 2023, down 14.21%, and an annual FY2024 reading of $388000.0, up 12.79% over the prior year.
  • Other financing activities was $344000.0 for Q1 2023 at Terns Pharmaceuticals, up from $257000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.7 million in Q2 2021 and bottomed at $33000.0 in Q1 2020.
  • Average Other financing activities over 4 years is $617714.3, with a median of $344000.0 recorded in 2023.
  • Peak annual rise in Other financing activities hit 3024.24% in 2021, while the deepest fall reached 3024.24% in 2021.
  • Year by year, Other financing activities stood at $825000.0 in 2020, then soared by 104.85% to $1.7 million in 2021, then plummeted by 84.79% to $257000.0 in 2022, then soared by 33.85% to $344000.0 in 2023.
  • Business Quant data shows Other financing activities for TERN at $344000.0 in Q1 2023, $257000.0 in Q4 2022, and $144000.0 in Q3 2022.